Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Shionogi
Shionogi
Obesity: Six trials to watch over the next 12 months
Obesity: Six trials to watch over the next 12 months
Clinical Trials Arena
obesity
clinical trials
Novo Nordisk
Altimmune
Innovent Biologics
Pfizer
Shionogi
Tonix
semaglutide
oxytocin
permvidutide
mazdutide
danuglipron
Flag link:
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline
BioSpace
Shionogi
M&A
Qpex Biopharma
antimicrobials
Flag link:
Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
Shionogi starts global Phase II clinical trial of redasemtide
Shionogi starts global Phase II clinical trial of redasemtide
Clinical Trials Arena
Shionogi
clinical trials
redasemtide
stroke
Flag link:
Shionogi's COVID-19 antiviral nabs Japanese approval to rival drugs from Pfizer, Merck
Shionogi's COVID-19 antiviral nabs Japanese approval to rival drugs from Pfizer, Merck
Fierce Pharma
Shionogi
COVID-19
antivirals
Japan
Flag link:
Shionogi's COVID-19 vaccine matches Pfizer's Comirnaty in booster trial
Shionogi's COVID-19 vaccine matches Pfizer's Comirnaty in booster trial
Fierce Biotech
Shionogi
vaccines
COVID-19
Japan
Pfizer
Flag link:
Shionogi files for approval of oral COVID-19 antiviral in Japan, brushing off missed clinical endpoint in race to market
Shionogi files for approval of oral COVID-19 antiviral in Japan, brushing off missed clinical endpoint in race to market
Fierce Biotech
Shionogi
Japan
antivirals
COVID-19
Flag link:
Shionogi licenses out 3rd-gen HIV asset to ViiV, notches a flop in chronic cough
Shionogi licenses out 3rd-gen HIV asset to ViiV, notches a flop in chronic cough
Fierce Biotech
Shionogi
HUV
ViiV Healthcare
clinical trials
chronic cough
sivopixant
Flag link:
One year after Fetroja approval, Shionogi expands label to include difficult-to-treat pneumonia
One year after Fetroja approval, Shionogi expands label to include difficult-to-treat pneumonia
Endpoints
Fetroja
Shionogi
hospital-acquired pneumonia
ventilator-associated bacterial pneumonia
FDA
Flag link:
Biopharma takeovers show quantity, if not quality
Biopharma takeovers show quantity, if not quality
EP Vantage
COVID-19
pandemic
M&A
Novo Nordisk
Corvidia
Gilead Sciences
Pionyr
Alexion
Portola Pharmaceuticals
Menarini
Stemline Therapeutics
Shionogi
Tetra Therapeutics
Flag link:
PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in biotech
PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in biotech
Endpoints
Shionogi
Alzheimer's disease
Tetra Therapeutics
M&A
Flag link:
Shionogi boosts Tetra Alzheimer's deal, nabs buyout option
Shionogi boosts Tetra Alzheimer's deal, nabs buyout option
Fierce Biotech
Shionogi
Tetra Therapeutics
R&D
M&A
Flag link:
Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'
Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'
Endpoints
Roche
Xofluza
Japan
Shionogi
Flu
influenza
Flag link:
After positive panel vote, Shionogi antibiotic scores US approval
After positive panel vote, Shionogi antibiotic scores US approval
Endpoints
Shionogi
antibiotics
FDA
cUTI
UTIs
Fetroja
Flag link:
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Endpoints
Shionogi
FDA
advisory panels
antibiotics
cefiderocol
UTIs
Flag link:
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
Endpoints
Shionogi
FDA
advisory panels
antibiotics
UTIs
cefiderocol
Flag link:
Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators
Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators
Endpoints
Shionogi
antibiotics
FDA
cefiderocol
nosocomial pneumonia
Flag link:
Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug
Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug
Endpoints
Shionogi
Europe
opioid-induced constipation
Symproic
Rizmoic
Flag link:
FDA Approves First New Flu Drug in Nearly 20 Years
FDA Approves First New Flu Drug in Nearly 20 Years
CP Wire
FDA
Xofluza
Flu
Shionogi
Roche
Tamiflu
Flag link:
Pages
1
2
3
next ›
last »